Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

被引：0
|
作者：
Elizabeth Head
Frederick A Schmitt
机构：
[1] Sanders-Brown Center on Aging,Department of Pharmacology and Nutritional Sciences
[2] University of Kentucky,Department of Neurology
[3] Sanders-Brown Center on Aging,undefined
[4] University of Kentucky,undefined
来源：
Alzheimer's Research & Therapy | / 6卷
关键词：
Dementia; Mild Cognitive Impairment; Down Syndrome; Intellectual Disability; Clinical Trial Outcome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Con: are we ready to translate Alzheimer's disease-modifying therapies to people with down syndrome?
    Head, Elizabeth
    Schmitt, Frederick A.
    ALZHEIMERS RESEARCH & THERAPY, 2014, 6 (05):
  • [2] Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?
    Rafii, Michael S.
    ALZHEIMERS RESEARCH & THERAPY, 2014, 6 (05):
  • [3] Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?
    Michael S Rafii
    Alzheimer's Research & Therapy, 6
  • [4] Assessing disease-modifying effects of norepinephrine in Down syndrome and Alzheimer's disease
    Ponnusamy, Ravikumar
    McNerney, M. Windy
    Moghadam, Shahrzad
    Salehi, Ahmad
    BRAIN RESEARCH, 2019, 1702 : 3 - 11
  • [5] Challenges in demonstrating the value of disease-modifying therapies for Alzheimer's disease
    Gustavsson, Anders
    Pemberton-Ross, Peter
    Montero, Melissa Gomez
    Hashim, Mahmoud
    Thompson, Robin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (06) : 563 - 570
  • [6] Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies
    Guo, Michael H.
    Vaishnavi, Sanjeev N.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2023, 25 (05) : 121 - 133
  • [7] Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
    Michael H. Guo
    Sanjeev N. Vaishnavi
    Current Treatment Options in Neurology, 2023, 25 : 121 - 133
  • [8] Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer's Disease and Related Disorders
    Iwatsubo, Takeshi
    JMA JOURNAL, 2022, 5 (03): : 307 - 313
  • [9] Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease
    Assuncao, Sheila Seleri
    Sperling, Reisa A.
    Ritchie, Craig
    Kerwin, Diana R.
    Aisen, Paul S.
    Lansdall, Claire
    Atri, Alireza
    Cummings, Jeffrey
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [10] Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
    Laurell, Axel A. S.
    Venkataraman, Ashwin V.
    Schmidt, Tatjana
    Montagnese, Marcella
    Mueller, Christoph
    Stewart, Robert
    Lewis, Jonathan
    Mundell, Clare
    Isaacs, Jeremy D.
    Krishnan, Mani S.
    Barber, Robert
    Rittman, Timothy
    Underwood, Benjamin R.
    BRITISH JOURNAL OF PSYCHIATRY, 2024, 224 (06) : 198 - 204
12345